Denosumab (Prolia) and Serum Calcium Levels
Prolia (denosumab) is associated with decreases in serum calcium rather than increases. [1] Severe hypocalcemia (low blood calcium) has been identified as a boxed warning risk, particularly in patients with advanced chronic kidney disease (including dialysis). [1]
Mechanism Linked to Calcium Changes
Denosumab inhibits osteoclast-mediated bone resorption, which reduces calcium release from bone into the circulation and can lower serum calcium. [1]
FDA Label Safety Findings on Calcium
The Prolia prescribing information includes a boxed warning for severe hypocalcemia in patients with advanced kidney disease. [1] The label advises evaluating serum calcium and mineral metabolism parameters before initiation in patients with advanced chronic kidney disease. [1] The label recommends reassessing serum calcium in patients predisposed to hypocalcemia after dosing. [2]
Clinical Trial Evidence for Direction of Change
In a randomized dose-ranging study in postmenopausal women, mean serum calcium demonstrated early small decreases after denosumab administration. [3] In a study in men receiving androgen-deprivation therapy, changes in serum calcium were described as transient decreases, with common grade 2 hypocalcemia incidence reported as less than 1%. [4]
Net Effect: Increase vs Decrease
Overall, Prolia results in lower serum calcium levels and carries a specific risk of hypocalcemia, rather than an expected increase in serum calcium. [1][3]
Situations With Highest Hypocalcemia Risk
The highest-risk group identified in regulatory communications and labeling is patients with advanced chronic kidney disease, especially those on dialysis. [1]
Monitoring and Prevention of Hypocalcemia
Calcium and vitamin D supplementation and calcium monitoring strategies are emphasized in Prolia labeling to reduce hypocalcemia risk. [1][2]
Answer to the Question
Prolia (denosumab) does not increase serum calcium levels as a general effect; it more commonly causes decreases in serum calcium and can cause severe hypocalcemia in high-risk patients. [1][3]